Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Tech

Fobi AI announces commercial launch of its PulseIR subsidiary; signs PanGenomic Health as first customer

Fobi AI (TSX-V:FOBI, OTCQB:FOBIF) Inc has announced the commercial launch of its wholly-owned PulseIR subsidiary with the signing of its first customer, PanGenomic Health Inc.

The data intelligence company said PulseIR is a platform as a service (PaaS) and will generate revenue through an annual license and initial setup fee.

“There’s no arguing that the world has experienced a major shift towards data-first digital transformation over the last few years,” Fobi AI (TSX-V:FOBI, OTCQB:FOBIF) CEO Rob Anson said in a statement.

READ: Fobi AI completes non-brokered private placement offering of units for aggregate gross proceeds of $826,690.55

“With the launch of PulseIR, we’re providing companies like PanGenomic with the automated tools to deliver a mobilized, data-driven activation and communications channel for investor relations,” Anson added.

The company noted that PulseIR, which supports Fobi’s investor relations (IR) platform Investor Pass, delivers a whole new experience of personalized engagement through real-time, mobile lock screen communication, bringing data-driven and digital approach to IR right into the palms of today’s new-age investors and provides shareholders with a direct understanding of price action, volume alerts, company news, events, and more.

Fobi added that PulseIR’s go-to-market launch with PanGenomic Health signifies a milestone growth opportunity as companies across industries look to connect and enhance their existing marketing infrastructure through automation.

PanGenomic offers a self-care digital platform to deliver personalized, evidence-based information about natural and plant-based health treatments, according to the company.

As well, Fobi reported that it has granted, pursuant to its Stock Option Plan, a total of 3,814,892 stock options to several company employees and officers to purchase up to 3,814,892 Fobi AI (TSX-V:FOBI, OTCQB:FOBIF) common shares.

The options were awarded at an exercise price of $0.325 per share, vest immediately, and expire five years from the grant date.

In part, the options are part of contractual obligations to certain employees and the company uses them as part of its strategy to incentivize and retain a strong team that will drive the company's growth, Fobi said.

Fobi AI (TSX-V:FOBI, OTCQB:FOBIF) is a cutting-edge data intelligence company that helps its clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits.

Contact Sean at sean@proactiveinvestors.com

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK